You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMesalazine
Accession NumberDB00244  (APRD01098)
TypeSmall Molecule
GroupsApproved
DescriptionAn anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)
Structure
Thumb
Synonyms
3-carboxy-4-hydroxyaniline
5-aminosalicylic acid
5-ASA
Asacol
Asacolitin
Canasa
Claversal
Fisalamine
Iialda
Lixacol
m-Aminosalicylic acid
Mesalamine
Mesalazina
Mesalazine
Mesalazinum
Mesasal
P-Aminosalicylsaeure
Pentasa
Rowasa
Salofalk
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
5-asaTablet, delayed release400 mgOralSanis Health Inc2010-11-022012-08-03Canada
AprisoCapsule, extended release375 mg/1OralSalix Pharmaceuticals, Inc.2008-10-31Not applicableUs
AprisoCapsule, extended release375 mg/1OralPhysicians Total Care, Inc.2010-08-18Not applicableUs
AsacolTablet, delayed release400 mg/1OralREMEDYREPACK INC.2012-03-30Not applicableUs
AsacolTablet, delayed release400 mg/1OralKAISER FOUNDATION HOSPITALS2012-02-23Not applicableUs
AsacolTablet, delayed release400 mg/1OralREMEDYREPACK INC.2011-03-092017-11-28Us
AsacolTablet, delayed release400 mg/1OralCardinal Health1992-04-01Not applicableUs
AsacolTablet, delayed release400 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
AsacolTablet, delayed release400 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
AsacolTablet, delayed release400 mg/1OralAmerican Health Packaging2012-01-232015-12-29Us
AsacolTablet400 mg/1OralREMEDYREPACK INC.2011-08-172016-11-08Us
AsacolTablet, delayed release400 mg/1OralWarner Chilcott (US), LLC1992-04-01Not applicableUs
AsacolTablet, delayed release400 mg/1OralCardinal Health1992-04-01Not applicableUs
AsacolTablet, delayed release400 mgOralWarner Chilcott Canada Co1993-12-31Not applicableCanada
AsacolTablet, delayed release400 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Asacol 800Tablet, delayed release800 mgOralWarner Chilcott Canada Co2005-06-13Not applicableCanada
Asacol HdTablet, delayed release800 mg/1OralWarner Chilcott (US), LLC2008-05-28Not applicableUs
Asacol HdTablet, delayed release800 mg/1OralAllergan, Inc.2008-05-28Not applicableUs
CanasaSuppository1000 mg/1RectalAllergan2001-01-05Not applicableUs
CanasaSuppository1000 mg/1RectalPhysicians Total Care, Inc.2010-08-18Not applicableUs
DelzicolCapsule, delayed release400 mg/1OralAllergan, Inc.2016-05-16Not applicableUs
DelzicolCapsule, delayed release400 mg/1OralCarilion Materials Management2013-03-01Not applicableUs
DelzicolCapsule, delayed release400 mg/1OralWarner Chilcott (US), LLC2016-03-312016-04-13Us
DelzicolCapsule, delayed release400 mg/1OralWarner Chilcott (US), LLC2013-03-01Not applicableUs
LialdaTablet, delayed release1.2 g/1OralKAISER FOUNDATION HOSPITALS2013-12-06Not applicableUs
LialdaTablet, delayed release1.2 g/1OralShire US Manufacturing Inc.2007-01-16Not applicableUs
MesalamineTablet, delayed release800 mg/1OralZydus Pharmaceuticals (USA) Inc.2016-08-01Not applicableUs
MesalamineCapsule500 mg/1OralPrasco Laboratories2004-07-08Not applicableUs
MesalamineTablet, delayed release800 mg/1OralAmerican Health Packaging2016-11-01Not applicableUs
MesalamineSuspension4 g/60mLRectalFranklin Pharmaceutical LLC2010-04-01Not applicableUs
MesalamineEnema4 g/60mLRectalANI Pharmaceuticals, Inc.2016-05-13Not applicableUs
MesalamineCapsule250 mg/1OralPrasco Laboratories1993-05-10Not applicableUs
MesasalTablet, delayed release500 mgOralGlaxosmithkline Inc1992-12-31Not applicableCanada
MezavantTablet, extended release1.2 gOralShire Pharma Canada Ulc2007-07-27Not applicableCanada
Ntp-5-aminosalicylic AcidTablet, delayed release400 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Pendo-5 AsaTablet, delayed release400 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PentasaTablet, extended release1.00 gOralFerring Inc2013-03-12Not applicableCanada
PentasaCapsule250 mg/1OralCarilion Materials Management1993-05-10Not applicableUs
PentasaCapsule250 mg/1OralCardinal Health1993-05-10Not applicableUs
PentasaCapsule250 mg/1OralAvera Mc Kennan Hospital2015-04-27Not applicableUs
PentasaCapsule250 mg/1OralShire US Manufacturing Inc.1993-05-10Not applicableUs
PentasaCapsule500 mg/1OralREMEDYREPACK INC.2011-10-042016-11-29Us
PentasaCapsule500 mg/1OralShire US Manufacturing Inc.2004-07-08Not applicableUs
Pentasa Enema 1g/100mlEnema; Liquid1 gRectalFerring Inc1995-12-31Not applicableCanada
Pentasa Enema 2g/100mlEnema; Liquid2 gRectalFerring Inc1995-12-312004-08-05Canada
Pentasa Enema 4g/100mlEnema; Liquid4 gRectalFerring Inc1995-12-31Not applicableCanada
Pentasa Extended-release Tablets 250mgTablet, extended release250 mgOralFerring Inc1995-12-312004-08-05Canada
Pentasa Extended-release Tablets 500mgTablet, extended release500 mgOralFerring Inc1994-12-31Not applicableCanada
Pentasa Suppository - 1gSuppository1 gRectalFerring Inc1995-12-31Not applicableCanada
RowasaEnema4 g/60mLRectalAlaven Pharmaceutical LLC1988-01-312017-09-30Us
RowasaSuspension4 g/60mLRectalMEDA Pharmaceuticals2016-03-29Not applicableUs
SalofalkSuspension2 gRectalAptalis Pharma Canada Inc1995-12-31Not applicableCanada
SalofalkSuppository500 mgRectalAptalis Pharma Canada Inc1995-12-31Not applicableCanada
SalofalkSuppository1000 mgRectalAptalis Pharma Canada Inc2000-06-01Not applicableCanada
SalofalkTablet, delayed release500 mgOralAptalis Pharma Canada Inc1995-12-31Not applicableCanada
SalofalkSuspension4 gRectalAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Salofalk (r) 5-asa Enteric Coated Tab- 250mgTablet, delayed release250 mgOralAxcan Pharma Inc1995-12-311998-08-03Canada
Salofalk (r) 5-asa Suppositories - 250mgSuppository250 mgRectalAxcan Pharma Inc1995-12-312006-09-12Canada
Sf RowasaSuspension4 g/60mLRectalAlaven Pharmaceutical LLC2009-09-012016-10-30Us
Sfrowasa Sulfite-free FormulationSuspension4 g/60mLRectalMEDA Pharmaceuticals2016-03-29Not applicableUs
Teva-5 AsaTablet, delayed release400 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MesalamineEnema4 g/60mLRectalGAVIS Pharmaceuticals, LLC2009-12-16Not applicableUs
MesalamineEnema4 g/60mLRectalPerrigo New York Inc2007-10-11Not applicableUs
MesalamineKitPerrigo New York Inc2009-09-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AsacolitinNot Available
ClaversalNot Available
FisalamineNot Available
LixacolNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4Q81I59GXC
CAS number89-57-6
WeightAverage: 153.1354
Monoisotopic: 153.042593095
Chemical FormulaC7H7NO3
InChI KeyKBOPZPXVLCULAV-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
IUPAC Name
5-amino-2-hydroxybenzoic acid
SMILES
NC1=CC(C(O)=O)=C(O)C=C1
Pharmacology
IndicationFor the treatment of active ulcerative proctitis.
Structured Indications
PharmacodynamicsMesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.
Mechanism of actionAlthough the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Arachidonate 5-lipoxygenaseProteinyes
inhibitor
HumanP09917 details
Peroxisome proliferator-activated receptor gammaProteinyes
agonist
HumanP37231 details
Inhibitor of nuclear factor kappa-B kinase subunit alphaProteinunknown
inhibitor
HumanO15111 details
Inhibitor of nuclear factor kappa-B kinase subunit betaProteinunknown
inhibitor
HumanO14920 details
MyeloperoxidaseProteinunknownNot AvailableHumanP05164 details
Arylamine N-acetyltransferaseProteinunknownNot AvailableMycobacterium tuberculosisP0A5L8 details
Related Articles
Absorption20 to 30% absorbed following oral administration. 10 to 35% absorbed from the colon (rectal suppository) - extent of absorption is determined by the length of time the drug is retained in the colon.
Volume of distributionNot Available
Protein bindingAbout 80% of N-Ac-5-ASA is bound to plasma proteins, whereas 40% of mesalamine is protein bound.
Metabolism

Rapidly and extensively metabolized, mainly to N-acetyl-5-ASA (Ac-5-ASA) in the intestinal mucosal wall and the liver. Ac-5-ASA is further acetylated (deactivated) in at least 2 sites, the colonic epithelium and the liver.

SubstrateEnzymesProduct
Mesalazine
Not Available
N-acetyl-5-ASA (Ac-5-ASA)Details
Route of eliminationApproximately 28% of the mesalamine in Asacol tablets is absorbed after oral ingestion, leaving the remainder available for topical action and excretion in the feces. It is excreted mainly by the kidney as N-acetyl-5-aminosalicylic acid.
Half lifeThe mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.
ClearanceNot Available
ToxicityOral, mouse: LD50 = 3370 mg/kg; Oral, rat: LD50 = 2800 mg/kg; Skin, rabbit: LD50 = >5 gm/kg. There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalazine absorption from the colon is limited.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Mesalazine is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mesalazine is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Mesalazine.Approved
AcarboseMesalazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololMesalazine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacAceclofenac may increase the nephrotoxic activities of Mesalazine.Approved
AcenocoumarolMesalazine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may increase the nephrotoxic activities of Mesalazine.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Mesalazine.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mesalazine.Approved, Vet Approved
AclarubicinMesalazine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneAdapalene may increase the nephrotoxic activities of Mesalazine.Approved
AlbiglutideMesalazine may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.Approved
AliskirenMesalazine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlogliptinMesalazine may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololMesalazine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Mesalazine.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alteplase.Approved
Aluminum hydroxideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum hydroxide.Approved
Aluminum phosphateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum phosphate.Approved
ALX-0081The risk or severity of adverse effects can be increased when Mesalazine is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Amcinonide.Approved
AmikacinMesalazine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMesalazine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Mesalazine.Approved
Ammonium chlorideThe serum concentration of Mesalazine can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AmrubicinMesalazine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Mesalazine.Approved
AncrodMesalazine may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Mesalazine is combined with Anecortave.Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Mesalazine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Anistreplase.Approved
annamycinMesalazine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may increase the nephrotoxic activities of Mesalazine.Approved
Antithrombin III humanMesalazine may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Mesalazine.Investigational
Aop200704Mesalazine may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanMesalazine may increase the anticoagulant activities of Apixaban.Approved
ApramycinMesalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
ArbekacinMesalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ardeparin.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Mesalazine.Approved, Investigational
ArotinololMesalazine may decrease the antihypertensive activities of Arotinolol.Approved
AsenapineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Astaxanthin.Investigational
AtenololMesalazine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may increase the nephrotoxic activities of Mesalazine.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Mesalazine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mesalazine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mesalazine.Approved
BalsalazideMesalazine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Batroxobin.Experimental
BecaplerminMesalazine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMesalazine may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Bemiparin.Approved
BenazeprilMesalazine may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.Approved
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Mesalazine.Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Mesalazine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Betamethasone.Approved, Vet Approved
BetaxololMesalazine may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidBetulinic Acid may increase the nephrotoxic activities of Mesalazine.Investigational
BevantololMesalazine may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mesalazine.Approved, Investigational
Bismuth SubcitrateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Bismuth Subcitrate.Approved
BisoprololMesalazine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMesalazine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMesalazine may decrease the antihypertensive activities of Bopindolol.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Brinzolamide.Approved
BromfenacBromfenac may increase the nephrotoxic activities of Mesalazine.Approved
BromocriptineMesalazine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the nephrotoxic activities of Mesalazine.Investigational
BucindololMesalazine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Budesonide.Approved
BufuralolMesalazine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMesalazine may decrease the diuretic activities of Bumetanide.Approved
BupranololMesalazine may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Mesalazine.Investigational
Calcium carbonateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Calcium carbonate.Approved
CanagliflozinMesalazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mesalazine.Approved
CandoxatrilMesalazine may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Mesalazine.Approved
CaptoprilMesalazine may decrease the antihypertensive activities of Captopril.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mesalazine.Approved
CarprofenCarprofen may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved, Withdrawn
CarteololMesalazine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMesalazine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the nephrotoxic activities of Mesalazine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Celecoxib.Approved, Investigational
CeliprololMesalazine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Certoparin.Approved
ChloroquineChloroquine may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.Approved, Vet Approved
ChlorpropamideMesalazine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mesalazine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ciclesonide.Approved, Investigational
CilazaprilMesalazine may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Mesalazine.Approved
CimetidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Cimetidine.Approved
CinoxacinMesalazine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMesalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidMesalazine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the nephrotoxic activities of Mesalazine.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Mesalazine.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mesalazine.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cortisone acetate.Approved
CurcuminCurcumin may increase the nephrotoxic activities of Mesalazine.Investigational
CyclosporineMesalazine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the nephrotoxic activities of Mesalazine.Investigational
Dabigatran etexilateMesalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dalteparin.Approved
DanaparoidMesalazine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinMesalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DaunorubicinMesalazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Mesalazine is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Mesalazine.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Mesalazine is combined with dehydroepiandrosterone sulfate.Investigational
dersalazineMesalazine may increase the anticoagulant activities of dersalazine.Investigational
DesirudinMesalazine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexketoprofen.Approved
DextranMesalazine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mesalazine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Mesalazine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Mesalazine may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mesalazine.Approved, Vet Approved
DiclofenacDiclofenac may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenamide.Approved
DicoumarolMesalazine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the nephrotoxic activities of Mesalazine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mesalazine.Approved
DihydrostreptomycinMesalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Mesalazine.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mesalazine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mesalazine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mesalazine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Mesalazine.Approved
DisopyramideMesalazine may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dorzolamide.Approved
DoxepinThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.Approved
DoxorubicinMesalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMesalazine may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Mesalazine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the nephrotoxic activities of Mesalazine.Approved
DulaglutideMesalazine may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the nephrotoxic activities of Mesalazine.Investigational
E6201E6201 may increase the nephrotoxic activities of Mesalazine.Investigational
EbselenEbselen may increase the nephrotoxic activities of Mesalazine.Investigational
Edetic AcidMesalazine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMesalazine may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinMesalazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilMesalazine may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMesalazine may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxacinMesalazine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Enoxaparin.Approved
EpinastineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Epinastine.Approved, Investigational
EpirizoleEpirizole may increase the nephrotoxic activities of Mesalazine.Approved
EpirubicinMesalazine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMesalazine may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Mesalazine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Mesalazine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mesalazine.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Mesalazine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Mesalazine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Equilin.Approved
EsmololMesalazine may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Esomeprazole.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone sulfate.Approved
Etacrynic acidMesalazine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptEtanercept may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateMesalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Mesalazine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Mesalazine.Approved
ExenatideMesalazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the nephrotoxic activities of Mesalazine.Investigational
FamotidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Famotidine.Approved
FenbufenFenbufen may increase the nephrotoxic activities of Mesalazine.Approved
FenoprofenFenoprofen may increase the nephrotoxic activities of Mesalazine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mesalazine.Vet Approved
FibrinolysinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fibrinolysin.Approved
FleroxacinMesalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mesalazine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fludrocortisone.Approved
FluindioneMesalazine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMesalazine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the nephrotoxic activities of Mesalazine.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mesalazine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flurandrenolide.Approved
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mesalazine.Approved, Nutraceutical, Vet Approved
FondaparinuxMesalazine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMesalazine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mesalazine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilMesalazine may decrease the antihypertensive activities of Fosinopril.Approved
FramycetinMesalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMesalazine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateMesalazine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMesalazine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMesalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mesalazine.Approved, Withdrawn
GemifloxacinMesalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMesalazine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMesalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMesalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Mesalazine.Approved, Nutraceutical
GliclazideMesalazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMesalazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMesalazine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideMesalazine may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinMesalazine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mesalazine is combined with HE3286.Investigational
HeparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Heparin.Approved, Investigational
HigenamineHigenamine may increase the nephrotoxic activities of Mesalazine.Investigational
HirulogMesalazine may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the nephrotoxic activities of Mesalazine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mesalazine.Approved, Investigational
HydralazineMesalazine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mesalazine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mesalazine.Approved
Hygromycin BMesalazine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Mesalazine.Approved, Investigational
IbuprofenIbuprofen may increase the nephrotoxic activities of Mesalazine.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Mesalazine.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Mesalazine.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Mesalazine.Approved, Nutraceutical
IdarubicinMesalazine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxMesalazine may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Mesalazine.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Mesalazine.Approved, Investigational
ImidaprilMesalazine may decrease the antihypertensive activities of Imidapril.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.Approved
IndenololMesalazine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Indobufen.Investigational
IndomethacinIndomethacin may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Mesalazine.Withdrawn
INNO-206Mesalazine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartMesalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMesalazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMesalazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMesalazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMesalazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMesalazine may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mesalazine.Approved, Investigational
IsoxicamIsoxicam may increase the nephrotoxic activities of Mesalazine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mesalazine is combined with Istaroxime.Investigational
KanamycinMesalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809The risk or severity of adverse effects can be increased when Mesalazine is combined with Kct 0809.Investigational
KebuzoneKebuzone may increase the nephrotoxic activities of Mesalazine.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Mesalazine.Investigational
KetoprofenKetoprofen may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mesalazine.Approved
KetorolacKetorolac may increase the nephrotoxic activities of Mesalazine.Approved
LabetalolMesalazine may decrease the antihypertensive activities of Labetalol.Approved
LanreotideMesalazine may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Lansoprazole.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mesalazine.Approved, Investigational
LeflunomideLeflunomide may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
LepirudinMesalazine may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMesalazine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMesalazine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mesalazine.Approved
LiraglutideMesalazine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilMesalazine may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Mesalazine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mesalazine.Approved
LomefloxacinMesalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamLornoxicam may increase the nephrotoxic activities of Mesalazine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mesalazine.Approved
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Mesalazine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mesalazine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mesalazine.Vet Approved
MagaldrateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magaldrate.Withdrawn
Magnesium carbonateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium carbonate.Approved
Magnesium hydroxideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium hydroxide.Approved
Magnesium oxideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.Approved
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Mesalazine.Approved
Magnesium TrisilicateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium Trisilicate.Approved
MasoprocolMasoprocol may increase the nephrotoxic activities of Mesalazine.Approved
ME-609The risk or severity of adverse effects can be increased when Mesalazine is combined with ME-609.Investigational
MecaserminMesalazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Medrysone.Approved
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Mesalazine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Melengestrol.Vet Approved
MeloxicamMeloxicam may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Mesalazine.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Mesalazine.Withdrawn
MetforminMesalazine may increase the hypoglycemic activities of Metformin.Approved
MethanthelineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mesalazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone.Approved, Vet Approved
MetiamideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Metiamide.Experimental
MetipranololMesalazine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.Approved
MetoprololMesalazine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMesalazine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneMesalazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolMesalazine may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Mesalazine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mesalazine.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Mesalazine.Investigational
MoexiprilMesalazine may decrease the antihypertensive activities of Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mesalazine.Approved
MoxifloxacinMesalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Mesalazine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nabumetone.Approved
NadololMesalazine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nadroparin.Approved
NafamostatNafamostat may increase the nephrotoxic activities of Mesalazine.Investigational
NaftifineNaftifine may increase the nephrotoxic activities of Mesalazine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Mesalazine.Investigational
Nalidixic AcidMesalazine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenNaproxen may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
NateglinideMesalazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mesalazine is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Mesalazine.Investigational
NeamineMesalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMesalazine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMesalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacNepafenac may increase the nephrotoxic activities of Mesalazine.Approved
NetilmicinMesalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Mesalazine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mesalazine.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mesalazine.Investigational
NizatidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Nizatidine.Approved
NorfloxacinMesalazine may increase the neuroexcitatory activities of Norfloxacin.Approved
OctreotideMesalazine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OfloxacinMesalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mesalazine.Approved, Investigational
OlopatadineOlopatadine may increase the nephrotoxic activities of Mesalazine.Approved
OlsalazineMesalazine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatMesalazine may decrease the antihypertensive activities of Omapatrilat.Investigational
OmeprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinOrgotein may increase the nephrotoxic activities of Mesalazine.Vet Approved
OtamixabanMesalazine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Mesalazine.Approved
OxaprozinOxaprozin may increase the nephrotoxic activities of Mesalazine.Approved
OxprenololMesalazine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Mesalazine.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pamidronate.Approved
PantoprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Parnaparin.Approved
ParomomycinMesalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PasireotideMesalazine may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinMesalazine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMesalazine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMesalazine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineMesalazine may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateMesalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Mesalazine.Approved, Investigational
PerindoprilMesalazine may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneMesalazine may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonMesalazine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
PindololMesalazine may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneMesalazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirarubicinMesalazine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMesalazine may decrease the diuretic activities of Piretanide.Experimental
PirfenidonePirfenidone may increase the nephrotoxic activities of Mesalazine.Investigational
PiroxicamPiroxicam may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
PlasminThe risk or severity of adverse effects can be increased when Mesalazine is combined with Plasmin.Investigational
PlicamycinMesalazine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mesalazine.Approved
PractololMesalazine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mesalazine.Approved
PramlintideMesalazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prasterone.Approved, Nutraceutical
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Mesalazine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pregnenolone.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Mesalazine.Approved
PropacetamolPropacetamol may increase the nephrotoxic activities of Mesalazine.Approved
PropranololMesalazine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mesalazine.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mesalazine.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mesalazine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mesalazine.Vet Approved
Protein CMesalazine may increase the anticoagulant activities of Protein C.Approved
Protein S humanMesalazine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMesalazine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMesalazine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the nephrotoxic activities of Mesalazine.Investigational
PuromycinMesalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilMesalazine may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mesalazine.Approved
QuinineMesalazine may increase the hypoglycemic activities of Quinine.Approved
RabeprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Rabeprazole.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Mesalazine.Investigational
RamiprilMesalazine may decrease the antihypertensive activities of Ramipril.Approved
RanitidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Ranitidine.Approved
RepaglinideMesalazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineMesalazine may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mesalazine.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Reteplase.Approved
ReviparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Reviparin.Approved
RibostamycinMesalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Mesalazine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Risedronate.Approved, Investigational
RivaroxabanMesalazine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rosiglitazone.Approved, Investigational
RosoxacinMesalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
Roxatidine acetateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Roxatidine acetate.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mesalazine.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Mesalazine.Approved
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Mesalazine.Approved, Vet Approved
SalsalateSalsalate may increase the nephrotoxic activities of Mesalazine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mesalazine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mesalazine.Investigational
SaxagliptinMesalazine may increase the hypoglycemic activities of Saxagliptin.Approved
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Mesalazine.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Mesalazine is combined with Selexipag.Approved
SeratrodastSeratrodast may increase the nephrotoxic activities of Mesalazine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mesalazine.Approved, Vet Approved
SisomicinMesalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinMesalazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SotalolMesalazine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMesalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMesalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMesalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilMesalazine may decrease the antihypertensive activities of Spirapril.Approved
SpironolactoneMesalazine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Mesalazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Streptokinase.Approved
StreptomycinMesalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMesalazine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineMesalazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleMesalazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineMesalazine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleMesalazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the nephrotoxic activities of Mesalazine.Approved
SulodexideMesalazine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mesalazine.Investigational
SunitinibMesalazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the nephrotoxic activities of Mesalazine.Approved, Withdrawn
TacrolimusMesalazine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mesalazine.Approved
TAK-390MRThe therapeutic efficacy of Mesalazine can be decreased when used in combination with TAK-390MR.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mesalazine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mesalazine.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mesalazine.Approved, Investigational
TemafloxacinMesalazine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilMesalazine may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the nephrotoxic activities of Mesalazine.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Mesalazine.Vet Approved
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Mesalazine.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Mesalazine.Investigational
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Mesalazine.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Mesalazine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tiludronate.Approved, Vet Approved
TimololMesalazine may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the nephrotoxic activities of Mesalazine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tinzaparin.Approved
TioguanineThe metabolism of Tioguanine can be decreased when combined with Mesalazine.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Mesalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tixocortol.Approved
TobramycinMesalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideMesalazine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideMesalazine may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Mesalazine.Approved
TolmetinTolmetin may increase the nephrotoxic activities of Mesalazine.Approved
TorasemideMesalazine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilMesalazine may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Mesalazine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Mesalazine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mesalazine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMesalazine may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mesalazine.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Mesalazine.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Mesalazine.Approved
TrovafloxacinMesalazine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mesalazine.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Mesalazine.Approved, Investigational
ValrubicinMesalazine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mesalazine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mesalazine.Approved
VerapamilVerapamil may increase the anticoagulant activities of Mesalazine.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Mesalazine.Approved
WarfarinMesalazine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMesalazine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Mesalazine may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Mesalazine.Approved
ZileutonZileuton may increase the nephrotoxic activities of Mesalazine.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Mesalazine.Withdrawn
ZorubicinMesalazine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Thomas M. Parkinson, Joseph P. Brown, Robert E. Wingard, Jr., “Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract.” U.S. Patent US4298595, issued January, 1975.

US4298595
General References
  1. Link [Link]
External Links
ATC CodesA07EC02
AHFS Codes
  • 56:36.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (67.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9471
Blood Brain Barrier-0.6168
Caco-2 permeable-0.8829
P-glycoprotein substrateNon-substrate0.8186
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9912
Renal organic cation transporterNon-inhibitor0.9314
CYP450 2C9 substrateNon-substrate0.8284
CYP450 2D6 substrateNon-substrate0.8331
CYP450 3A4 substrateNon-substrate0.7636
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8712
CYP450 2D6 inhibitorNon-inhibitor0.9744
CYP450 2C19 inhibitorInhibitor0.6752
CYP450 3A4 inhibitorNon-inhibitor0.6628
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9023
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7922
BiodegradationReady biodegradable0.6197
Rat acute toxicity1.7065 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9759
hERG inhibition (predictor II)Non-inhibitor0.9715
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Salix pharmaceuticals inc
  • Shire development inc
  • Perrigo israel pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Alaven pharmaceutical llc
  • Axcan pharma us inc
  • Warner chilcott pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral375 mg/1
TabletOral400 mg/1
Tablet, delayed releaseOral400 mg/1
Tablet, delayed releaseOral400 mg
Tablet, delayed releaseOral800 mg
Tablet, delayed releaseOral800 mg/1
SuppositoryRectal1000 mg/1
Capsule, delayed releaseOral400 mg/1
Tablet, delayed releaseOral1.2 g/1
EnemaRectal4 g/60mL
Kit
SuspensionRectal4 g/60mL
Tablet, delayed releaseOral500 mg
Tablet, extended releaseOral1.2 g
CapsuleOral250 mg/1
CapsuleOral500 mg/1
Tablet, extended releaseOral1.00 g
Enema; liquidRectal1 g
Enema; liquidRectal2 g
Enema; liquidRectal4 g
Tablet, extended releaseOral250 mg
Tablet, extended releaseOral500 mg
SuppositoryRectal1 g
SuppositoryRectal1000 mg
SuppositoryRectal500 mg
SuspensionRectal2 g
SuspensionRectal4 g
Tablet, delayed releaseOral250 mg
SuppositoryRectal250 mg
Prices
Unit descriptionCostUnit
Canasa 30 1000 mg Suppository Box488.32USD box
Canasa 1000 mg suppository13.88USD suppository
Salofalk (4 g/60 g) 4 g/enm Enema6.73USD enema
Canasa 500 mg suppository6.24USD suppository
Pentasa (4 g/100 Ml) 4 g/enm Enema5.02USD enema
Pentasa (1 g/100Ml) 1 g/enm Enema4.17USD enema
Salofalk (2 g/60 g) 2 g/enm Enema3.96USD enema
Asacol hd dr 800 mg tablet3.88USD tablet
Pentasa 500 mg capsule2.66USD capsule
Asacol 400 mg Enteric Coated Tabs2.22USD tab
Asacol ec 400 mg tablet1.94USD tablet
Salofalk 1000 mg Suppository1.81USD suppository
Pentasa 1 g Suppository1.8USD suppository
Salofalk 500 mg Suppository1.23USD suppository
Asacol 800 800 mg Enteric-Coated Tablet1.14USD tablet
Pentasa 250 mg capsule1.07USD capsule
Mesasal 500 mg Enteric-Coated Tablet0.69USD tablet
Pentasa 500 mg Sustained-Release Tablet0.63USD tablet
Asacol 400 mg Enteric-Coated Tablet0.59USD tablet
Salofalk 500 mg Enteric-Coated Tablet0.56USD tablet
Novo-5 Asa 400 mg Enteric-Coated Tablet0.42USD tablet
Rowasa 4 gm/60 ml enema0.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2111697 No2002-08-202012-06-16Canada
CA2444814 No2009-06-092021-10-24Canada
US5541170 No1993-07-302013-07-30Us
US6551620 No1998-04-202018-04-20Us
US6649180 No2000-04-132020-04-13Us
US6773720 No2000-06-082020-06-08Us
US6893662 No2001-11-152021-11-15Us
US7645801 No2007-07-242027-07-24Us
US8217083 No2008-06-062028-06-06Us
US8337886 No1998-04-202018-04-20Us
US8436051 No2008-06-062028-06-06Us
US8496965 No1998-04-202018-04-20Us
US8580302 No2001-11-152021-11-15Us
US8865688 No2010-05-012030-05-01Us
US8911778 No1998-04-202018-04-20Us
US8940328 No1998-04-202018-04-20Us
US8956647 No1998-04-202018-04-20Us
US9089492 No2001-11-152021-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point283 °CPhysProp
water solubility0.84 g/L at 20°CNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.2 mg/mLALOGPS
logP0.75ALOGPS
logP-0.29ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)2.02ChemAxon
pKa (Strongest Basic)5.87ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity40 m3·mol-1ChemAxon
Polarizability14.26 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.48 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Aminobenzoic acid
  • Benzoic acid
  • Substituted aniline
  • Benzoyl
  • Aminophenol
  • Phenol
  • Aniline
  • Primary aromatic amine
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [PubMed:14742690 ]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [PubMed:12463455 ]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [PubMed:16855178 ]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [PubMed:12208114 ]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [PubMed:2882965 ]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [PubMed:6428914 ]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [PubMed:6131674 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11. [PubMed:15824083 ]
  2. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9. [PubMed:18544567 ]
  3. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625 ]
  4. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications...
Gene Name:
CHUK
Uniprot ID:
O15111
Molecular Weight:
84638.88 Da
References
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [PubMed:11151876 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These mo...
Gene Name:
IKBKB
Uniprot ID:
O14920
Molecular Weight:
86563.245 Da
References
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [PubMed:11151876 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181 ]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
nat
Uniprot ID:
P0A5L8
Molecular Weight:
Not Available
References
  1. Tucker MA, Smith TJ: Acetylation of 5-aminosalicylate by hamster colon arylamine N-acetyltransferase. J Appl Toxicol. 1990 Feb;10(1):73-4. [PubMed:2335716 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:40